Neurogene Inc. has approved a grant of non-qualified stock options to purchase 2,820 shares of the company’s common stock for a new employee, with the options granted under the company’s 2025 Inducement Plan. The options have an exercise price equal to the closing price of Neurogene’s common stock on the grant date of February 2, 2026. Vesting will occur over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the following three years, contingent on continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260204466670) on February 04, 2026, and is solely responsible for the information contained therein.